Stock Analiz

OmniAb, Inc. OABI

Biotechnology: Commercial Physical & Biological Resarch · IPO 2021 · data as of November 13, 2026

$4.91Market cap $716M
Open the interactive analysis →

OmniAb, Inc. (OABI) is a healthcare company listed in the US with a market value of about $716M. In the twelve months to September 30, 2026 it had revenue of $40M and net income of -$43M, a net margin of -108.1%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).

Key numbers: a price to free cash flow of 300.9, a 5-year average ROIC of -16%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 96% below the current price.

About OmniAb

OmniAb is listed in the US and classified in biotechnology: commercial physical & biological resarch, IPO year 2021. Revenue went from $35M in 2021 to $19M in 2025, a decline of about 14.4% a year. It was profitable in 0 of the last 5 years in our data. Its share count rose by 33% over three years (dilution for shareholders). It spends 256% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health3/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Positive free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF300.9
P/S17.8
P/B2.9
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield0.3%
Shareholder yield0.0%
Intrinsic value vs. price−96%

Growth and quality

Revenue growth (1 yr)-29.3%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-169.2%
ROIC (5-yr avg.)-15.6%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 5 years

Fiscal yearTTM20252024202320222021
Revenue$40M$19M$26M$34M$59M$35M
Net income-$43M-$65M-$62M-$51M-$22M-$27M
Free cash flow$2M-$37M-$42M$703000-$21M-$10M
EPS (diluted)$-0.34$-0.57$-0.61$-0.51$-0.26$-0.33
Net margin-108.1%-347.0%-235.0%-148.2%-37.8%-77.8%
ROIC—-23.4%-20.8%-16.1%-6.2%-11.3%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 6 analysts is $8.33, 70% above the current price; targets range from $5.00 to $12.00; the consensus rating is “Strong buy”; expected EPS is $-0.35 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is OmniAb stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 96% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does OmniAb pay a dividend?

Not currently.

Is OmniAb a good stock to buy?

We do not give buy or sell advice. OmniAb scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.